Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its first quarter 2021 financial results after markets close on May 5th. A live conference call is scheduled for May 6th at 7:00 AM CT to discuss the financial results and provide a business update. Interested participants can join via phone or through a webcast, which will also be available for playback on the company's website for 12 months. A telephonic replay will be accessible until May 13, 2021. For further details, visit www.diamedica.com.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls will present at the B. Riley Neuroscience Investor Conference on April 29th at 11:30am ET. The company will also be available for one-on-one meetings at the event, with investors encouraged to schedule these through B. Riley. The recorded presentation will be accessible on DiaMedica’s website starting April 29th.
DiaMedica focuses on developing treatments for neurological disorders and kidney diseases, aiming to enhance patient quality of life.
DiaMedica Therapeutics (Nasdaq: DMAC) announced its participation in the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings, conducted virtually from April 6-10, 2021. The company will present two abstracts: the REDUX Study on DM199 for chronic kidney disease and a study on KLK1 levels in kidney patients. These abstracts will be available through the NKF mobile app and DiaMedica's website post-event. DM199 is a recombinant form of human tissue kallikrein-1, currently under investigation for its effectiveness in treating neurological and kidney disorders.
DiaMedica Therapeutics (Nasdaq: DMAC) announced significant developments in its clinical trials and financial results for 2020. The FDA accepted DMAC's request for a Type B meeting regarding DM199 for acute ischemic stroke, allowing for a streamlined Phase 2/3 trial with about 350 participants. The company reported $27.5 million in cash and equivalents, enough to fund operations through mid-2022. DMAC's R&D expenses increased to $8.3 million, largely due to the REDUX trial. Conference call for results is scheduled for March 11, 2021.
DiaMedica Therapeutics (Nasdaq: DMAC) has announced its participation in the American Heart Association 2021 International Stroke Conference. During the event, taking place from March 17-19, 2021, the company will present a plenary talk on the safety and tolerability of its recombinant human tissue kallikrein (DM199) for treating acute ischemic stroke, based on a randomized clinical trial. This conference is a leading global event focused on cerebrovascular disease. For more details, visit the conference's website.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will host a KOL webinar on DM199, its leading asset for Acute Ischemic Stroke (AIS) treatment, on March 19, 2021. Key opinion leaders Scott Kasner, M.D., and Paolo Madeddu, M.D., will discuss treatment gaps and DM199's potential benefits. Management will update on DM199, a synthetic form of human tissue kallikrein-1, which showed a statistically significant 86% reduction in severe recurrent strokes in a recent study. An IND application for a phase 2/3 study is planned for Q1 2021.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced its participation in three investor conferences in March 2021. The conferences include the 33rd Annual Roth Conference on March 15, where management will engage in a fireside chat and 1-on-1 meetings. The Oppenheimer’s 31st Annual Healthcare Conference is scheduled for March 16, featuring a corporate presentation and 1-on-1 meetings. Lastly, the Maxim’s Emerging Growth Conference will take place on March 17, also including a corporate presentation and 1-on-1 meetings.
DiaMedica Therapeutics (Nasdaq: DMAC) will release its Q4 2020 financial results after market close on March 10, 2021. A live conference call to discuss these results and a business update is scheduled for March 11, 2021, at 7:00 AM CT. Interested listeners can access the call via phone or a simultaneous webcast, and a playback will be available for 12 months. The conference ID for the call is 9297319. For more information, visit www.diamedica.com.
DiaMedica Therapeutics (Nasdaq: DMAC) has announced that Dr. Harry Alcorn, Chief Medical Officer, will present a research update on CKD DM199 at the 3rd Chronic Kidney Disease Drug Development summit on March 2, 2021, at 1:00 PM ET. The presentation will cover data from the CKD Phase 1b study and the design of the Phase II Redux study. The CKD3 summit is a key event for discussing innovative treatments for chronic kidney disease, bringing together industry leaders to evaluate current drug pipelines and emerging therapies.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is set to present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The conference will be held virtually, and the recorded presentation will be accessible on the company's website starting January 11. DiaMedica focuses on creating innovative treatments for chronic kidney diseases and neurological disorders. Investors can find more information about the presentation and the company on their official website.